linjc16/ctgov huggingface dataset:
Study of Cerebral Glucose Metabolism in Neurodegenerative Diseases and Head Trauma

Study Overview
=================
Brief Summary
-----------------
The reason why each specific degenerative disease is characterized by a different FDG PET pattern is still unclear today. There are four main hypotheses proposed to explain this selective vulnerability: 1) Nodal stress, theory according to which the main nodes of specific brain networks undergo wear and tear, 2) trans-neuronal diffusion, theory according to which some toxic agents/proteins or altered propagate along network connections through Prion-like mechanisms, 3) trophic failure, in which the interruption of inter-modal connectivity causes the loss of collateral trophic factors, and finally 4) shared vulnerability in which regions also distant from each other are part of a common network which gives a susceptibility uniformly distributed throughout the network. FDG PET provides in-vivo information on the distribution of brain synaptic dysfunction prior to complete neural death, and represents the main in vivo biomarker of neural dysfunction associated with different clinical conditions characterized by neurodegeneration phenomena. For this reason, FDG PET is considered a fundamental approach to shed light on the causes of selective brain vulnerability in various pathological conditions.

Official Title
-----------------
Study of Cerebral Glucose Metabolism in Neurodegenerative Diseases and Head Trauma: Retrospective Review of an Large Cohort of FDG PET Data

Conditions
-----------------
Neurodegenerative Diseases

Intervention / Treatment
-----------------
* Diagnostic Test: FDG PET


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: presence of diagnosis of neurodegenerative disease. Exclusion Criteria: patients< 18 years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: FDG PET|Distribution pattern of the FDG tracer in patients with neurodegenerative diseases and identify the regions of altered brain function specific for each clinical condition.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| FDG PET to measure brain areas of hypo or hyper regional metabolism in patients with neurodegenerative disease. | Characterization of the different pathologies examined starting from the study of regional metabolism in individual subjects up to the study of the functional activity of the different brain circuits. | 4 years |
Assessment of Knowledge and Attitude Toward Obstructive Sleep Apnea in Medical Teams

Study Overview
=================
Brief Summary
-----------------
Obstructive sleep apnea (OSA) is a serious and often underreported condition, despite its highly prevalent distribution. Medical teams play an integral role in screening and managing patients with a high risk of developing OSA.

Official Title
-----------------
Assessment of Knowledge and Attitude Toward Obstructive Sleep Apnea in Medical Teams: Multicenter Study

Conditions
-----------------
OSA

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Medical teams including: Students of medical schools and dentistry General practitioners Dentists Medical specialists Highly trained nurses (HIN) Exclusion Criteria: Non- medical personnel's

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| explores the knowledge and attitude towards OSA among medical teams | frequency | 3 months |
Influence of Intravitreal Aqueous Tamponade on Lens Status and Ocular

Study Overview
=================
Brief Summary
-----------------
To observe the effects of vitreous cavity Balanced salt solution (BSS) tamponade on the state of the lens and related parameters of the eye, and whether the changes of the above parameters are correlated with age, gender, diabetes or not, etc., so as to provide references for the diagnosis and treatment of related diseases and scientific research.

Official Title
-----------------
Influence of Intravitreal Aqueous Tamponade on Lens Status and Ocular

Conditions
-----------------
Aqueous Tamponade, Cataract

Intervention / Treatment
-----------------
* Procedure: pars plana vitrectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ① Patients undergoing vitrectomy for diabetic retinopathy, epiretinal membranes, macular hole, retinal detachment, and other diseases; Patients who underwent vitreous silicone oil tamponade and vitreous silicone oil removal due to various causes; ③ Intraoperative BSS was used for fill the vitreous cavity; ④ Before treatment, inform the patient that the clinical data may be used in clinical research, and the patient and his family are informed and sign the informed consent. Exclusion Criteria: ① The operation eye was intraocular lens or cataract extraction during operation; ② Suspensory ligament relaxation or rupture, ciliary body detachment or transaction, lens dislocation, endophthalmitis, traumatic cataract; intraoperative lens injury; ④ patients who refused to participate in the study.

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| PPV（pars plana vitrectomy） group<br> | Procedure: pars plana vitrectomy<br>* pars plana vitrectomy and Silicone oil removal to distinguish subjects<br>* Other names: Silicone oil removal;|
| Silicone oil removal group<br> | Procedure: pars plana vitrectomy<br>* pars plana vitrectomy and Silicone oil removal to distinguish subjects<br>* Other names: Silicone oil removal;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| degree of lens opacity |  | 1 year | 
| lens thickness |  | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| anterior chamber depth |  | 1 year | 
| axial length |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
aqueous tamponade, cataract, lens thickness, axial length, pars plana vitrectomy
A Questionnaire Survey Study for Exploring Outcomes for Patients With Disc Herniation

Study Overview
=================
Brief Summary
-----------------
Background: The selection of primary outcomes that reflect the real symptoms and conditions of patients is instrumental in clinical studies on the effectiveness of specific treatment modalities. This study aimed to explore the appropriate outcomes that reflect the real-world needs and concerns of patients with lumbar disc herniation (LDH) and provide a basis for designing related clinical trials. Methods and Findings: This cross-sectional nationwide web-based survey study was conducted in South Korea in November 2022. Patients who were diagnosed with LDH and had LDH-related radiating leg pain were enrolled. The questionnaire consisted of 5 parts: basic characteristics, disease onset, symptom and severity, priority symptoms for improvement, and important factors in treatment. Overall, 500 patients (100 patients from the each age group) were enrolled.

Official Title
-----------------
Are Primary Outcomes Really Primary? A Questionnaire Survey Study for Exploring Outcomes for Patients With Disc Herniation Reflecting Real Patient Symptoms and Needs

Conditions
-----------------
Lumbar Disc Herniation

Intervention / Treatment
-----------------
* Other: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diagnosed of LDH age 19-69 years presence of LDH-related symptoms such as pain, numbness, weakness, or tingling in the legs agree to informed consent form Exclusion Criteria: severe mental illness and intellectual disabilities that prevented independence in answering the questionnaire

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 69 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Diagnosed with LDH and had LDH-related radiating leg pain<br> | Other: No intervention<br>* This is a survey study, and there were no intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| survey basic characteristics |  | 1 day | 
| disease onset survey |  | 1 day | 
| symptom and its severity survey |  | 1 day | 
| priority symptoms for improvement survey |  | 1 day | 
| important factors in treatment survey |  | 1 day |
Impact of Modifications to the Rendering of the Antibiogram on the Prescriptions of Meropenem in Pseudomonas Bacteremia

Study Overview
=================
Brief Summary
-----------------
Modification of the rendering of the antibiogram at the Strasbourg University Hospital in November 2019 with the appearance of the concept of standard dose or high dose sensitivity. This modification seems to have favored an inappropriate overprescription of Meropenem (the only antibiotic made at standard dose) in Pseudomonas infections sensitive to other beta-lactams. In June 2021, it was therefore decided to mask sensitivity to carbapenems by default in the rendering of Pseudomonas antibiograms when the strain was sensitive to a narrower spectrum beta-lactam (restricted antibiogram). The aim of this study is to evaluate the impact of these changes in the antibiogram on antibiotic prescriptions.

Official Title
-----------------
Impact of Modifications to the Rendering of the Antibiogram on the Prescriptions of Meropenem in Pseudomonas Bacteremia

Conditions
-----------------
Pseudomonas

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Major subject (≥18 years old) Subject with a positive blood culture result for Pseudomonas spp identified in the microbiology laboratory of Strasbourg University Hospital during the period from June 1, 2018 to November 30, 2022 Subject not opposing the reuse of their data for the purposes of this research. Exclusion Criteria: Subject having expressed opposition to participating in the study, Pseudomonas spp strain resistant to all first-line beta-lactams (Piperacillin-Tazobactam, Ceftazidime, Céfepime and Aztreonam). Pseudomonas spp strain resistant to Meropenem. Lack of information on the antibiotic treatment undertaken.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of Meropenem prescriptions in Pseudomonas spp bacteraemia susceptible to narrow-spectrum betalactams | This study is retrospective, the analysis focuses on the medical records of patients treated at the Strasbourg University Hospital between June 1, 2018 and November 30, 2022. | Files analysed retrospectively from June 1, 2018 to November 30, 2022 will be examined | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pseudomonas, Meropenem, Microbial susceptibility testing, EUCAST breakpoint, Antibiotic stewardship
ddcfDNA in Kidney Transplant Recipients

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to predict subclinical Antibody-Mediated Rejection (ABMR) occurrences in de novo DSA-positive recipients maintaining stable renal function after transplantation. This will be achieved through the measurement of donor-derived cell-free DNA. The utility of donor-derived cell-free DNA will be validated based on histological findings using Receiver Operating Characteristics (ROC) curve analysis.

Official Title
-----------------
The Efficacy of Donor-derived Cell-free DNA as a Biomarker for Subclinical Antibody-mediated Rejection in de Novo Anti-HLA DSA-positive Recipients Who Maintain Stable Renal Function After Kidney Transplantation

Conditions
-----------------
Kidney Transplant Rejection

Intervention / Treatment
-----------------
* Genetic: AlloSeq cfDNA


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Recipients aged 18 and above Patients with de novo DSA positivity post-kidney transplantation and stable renal function: De novo HLA DSAs encompass both class I and class II, with Mean Fluorescence Intensity (MFI) greater than 1000. Stable renal function is defined as serum creatinine variation of less than 15% compared to the last 6 months. Patients with detected de novo HLA-DSAs but did not undergo histological examinations. Exclusion Criteria: Multi-organ transplant recipients Recipients with positive preformed DSAs ABO-incompatible transplant recipients Pediatric recipients under 18 years old at the time of transplantation Recipients lost to follow-up observation atients already subjected to histological examinations due to positive De novo HLA-DSAs.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Genetic: AlloSeq cfDNA|An in vitro diagnostic medical device is employed for predicting damage to and rejection of transplanted organs (kidney, heart, liver, lung) by measuring the ratio of Donor-Derived Cell-Free DNA (dd-cfDNA) to total Cell-Free DNA (cfDNA) extracted from the plasma of patients who have undergone solid organ transplantation. This measurement is carried out using next-generation sequencing methods.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| diagnostic accuracy of subclinical ABMR |  | 10 years within kidney transplantation |
Prophylactic Pregabalin Treatment Following Spinal Cord Injury

Study Overview
=================
Brief Summary
-----------------
Patients arriving to rehabilitation up to 2 months following SCI will be given (study group) or not (control group) Lyrica (75X2). They will be followed for central pain development.

Detailed Description
-----------------
Patients arriving to rehabilitation up to 2 months following SCI will be recruited, if they have not yet developed central pain. Two thirds (the study group) will be treated with Lyrica (Pregabalin75X2) for 3 months. One third (the control group) will not receive preventative treatment. Participants will be followed for central pain development.

Official Title
-----------------
The Effect of Preventional Drug Therapy on Pain Regulation Mechanisms Among Spinal Cord Injury Patients Who Have Yet to Develop Central Pain

Conditions
-----------------
Spinal Cord Injuries, Spinal Cord Diseases

Intervention / Treatment
-----------------
* Drug: Pregabalin 75mg


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: spinal cord injury / lesion below C3. up to 2 months from onset Exclusion Criteria: Pregnancy other medical conditions that might influence sensation pain (chronic or acute) Creatinine>1.2 mg/DL Lactose sensitivity

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: allocation will be sequential. 2 patients will be in the study group, followed by one patient at the control group.
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Pregabalin<br>Pregabalin 75 mg X2 | Drug: Pregabalin 75mg<br>* Pregabalin 75 mg twice a day<br>* Other names: Lyrica;|
| No Intervention: No treatment<br>no treatment | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Central pain | development of central pain | 1 year |
ICP Threshold After Decompressive Craniectomy

Study Overview
=================
Brief Summary
-----------------
Severe traumatic brain injury (sTBI) is a critical disease of public health importance. Increased intracranial play a significant role in the secondary injury of TBI. Reducing the ICP is helpful in reducing the mortality of sTBI. The threshold of ICP for sTBI has been suggested. The threshold of ICP for sTBI after decompressive craniectomy is not clear.

Detailed Description
-----------------
240 sTBI patients who meet the inclusion criteria will be enrolled in the present study. All sTBI patients will be screened. If meeting the including criteria, the investigators will contact the family, explain the study, and send a consent form for review. After obtaining written consent from the family, the ICP and blood pressure will be monitored continuously until retraction of ICP sensor. A mean ICP of each patient will be calculated. The neurological outcome will be assessed at 180 days after injury. A threshold for ICP after decompressive craniectomy will be derived by analyzing the association between mean ICP and neurological outcome.

Official Title
-----------------
ICP Threshold of Severe Traunatic Brain Injury After Decompressive Craniectomy

Conditions
-----------------
Traumatic Brain Injury

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: history of traumatic brain injury age: 18-80 years admission GCS score≤8 admitting to hospital with 24 hours after injury received decompressive craniectomy received invasive ICP monitoring Exclusion Criteria: refuse follow-up received operation before admitting to hospital received cardio-pulmonary resuscitation after injury disturbance of consciousness caused by non-traumatic reasons prior history of traumatic brain injury or stroke expected lifetime less than 180 days admitting to other ongoing study systemic disease: uremia, liver cirrhosis, malignant tumor, mental disease, drug or alcohol dependence

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Modified Glasgow Outcome score | neurological outcome | 180 days after injury |
Application of New Magnetic Resonance UTE Technique in Hip Joint Lesions

Study Overview
=================
Brief Summary
-----------------
Explore the imaging and quantitative monitoring of hip bone, cartilage and ligament by magnetic resonance UTE technology, combined with QCT and DXA technology, to provide a more accurate basis for clinical evaluation and treatment.

Detailed Description
-----------------
Osteoporosis is a systemic bone metabolism-related disease characterized by decreased bone mass per unit volume, increased bone fragility, decreased bone density, thinning of the bone cortex and changes in bone microstructure. It often occurs in the lumbar spine and hip joint. Femoral neck fracture is a common complication of hip osteoporosis, which seriously affects people's quality of life. UTE technology can clearly image and quantify human cortical bone and cancellous bone, and advanced UTE technology such as STAIR-UTE and UTE-MT have made some progress in the field of osteoporosis. The purpose of this study was to explore UTE technology for imaging and quantitative study of cortical bone, cancellous bone and cartilage of hip joint, and to find more accurate imaging methods for clinical evaluation of hip osteoporosis and other diseases.

Official Title
-----------------
Application of New Magnetic Resonance Technique-UTE in Hip Joint Lesions

Conditions
-----------------
Hip Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with past or suspected osteoporosis and bone loss; Patients with previous femoral neck fracture; Patients with avascular necrosis of femoral head; Hip osteoarthritis patients. Exclusion Criteria: Patients with metal implants in corresponding parts; Claustrophobic.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| normal group<br>There are no lesions on the hip. | |
| abnormal group<br>There are some lesions on the hip. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| proton density fat fraction (PDFF) | Magnetic resonance proton density fat fraction | Baseline (before surgery) | 
| T2 relaxation rate | R2* | Baseline (before surgery) | 
| Magnetization Transfer Ratio (MTR) | magnetization transfer ratio | Baseline (before surgery) | 
| T1rho | spin-lattice relaxation in the rotation ame | Baseline (before surgery) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Subjective rating values | rating values | Baseline (before surgery) |